Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;60(6):1587-1590.
doi: 10.1080/10428194.2018.1543885. Epub 2019 Jan 8.

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes

Nour Abuhadra  1 , Sudipto Mukherjee  1 , Karam Al-Issa  1 , Vera Adema  2 , Cassandra M Hirsch  2 , Anjali Advani  1 , Bartlomiej Przychodzen  2 , Ahed Makhoul  1 , Hassan Awada  2 , Jaroslaw P Maciejewski  2 , Mikkael A Sekeres  1 , Aziz Nazha  1
Affiliations

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes

Nour Abuhadra et al. Leuk Lymphoma. 2019 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1543885.

Figures

Figure 1.
Figure 1.
Clustered mutation profiles and mutation maps for BCOR and BCORL1.
Figure 2.
Figure 2.
Survival curves for BCOR and BCORL1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–1885. - PubMed
    1. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–247. - PMC - PubMed
    1. Nazha A, Al-Issa K, Hamilton BK, et al. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia. 2017;31:2848–2850. - PubMed
    1. Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214–2220. - PubMed
    1. Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013;122:3169–3177. - PubMed